A multi-center open label phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis.
Project objectivesEvaluate the hematological response (CR + VGPR) upon completion of 6 cycles Daratumumab plus pomalidomide in patients with AL amyloidosis who have relapsed or refractory, who have not achieved VGPR or best response after one previous line of therapy. |
Start and end date |
| 23th November 2021 |
Project Manager |
| Ombretta Annibali - Principal Investigator |
Coordinating institution of the project |
| IRCCS San Matteo polyclinic in Pavia |
Other Institutions involved |
|
Funding source(s). |
• INDEPENDENT RESEARCH PROJECT ON DRUGS - INTERVENTIONAL TRIALS - NOTICE 2017 AIFA code -TRS-2018-00001624
Economic value of the project62.400 € |
